Biotechnology

124 articles in this category (Page 4 of 6)

Stock Weather AIBiotechnologyClinical Trials

Belite Bio – 2025-12-29 - Increase Confidence 8/10

Strong cash position and recent positive Phase 3 trial results act as catalysts for near-term upside despite ongoing negative free cash flow.

Dec 29, 2025BLTE

Stock Weather AIBiotechnologyMomentum Investing

Praxis Precision Medicines – 2025-12-29 - Increase Confidence 8/10

Negative free cash flow contrasts with FDA breakthrough designation for ulixacaltamide, triggering momentum surge and near-term upside potential.

Dec 29, 2025PRAX

Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2025-12-25 - Increase Confidence 8/10

Negative free cash flow contrasts with positive Phase 2 trial data for EDG-7500, triggering investor optimism and a near-term price catalyst for EWTX.

Dec 25, 2025EWTX

Stock Weather AIBiotechnologyEarnings Momentum

Travere Therapeutics – 2025-12-25 - Increase Confidence 8/10

Strong revenue growth and recent profitability shift, combined with bullish analyst momentum and upcoming FDA catalyst, signal near-term upside.

Dec 25, 2025TVTX

Stock Weather AIBiotechnologyAnalyst Sentiment

Edgewise Therapeutics Inc. – 2025-12-24 - Increase Confidence 8/10

Negative free cash flow offset by strong analyst momentum and recent upgrades, signaling near-term upside driven by clinical pipeline anticipation.

Dec 24, 2025EWTX

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-12-23 - increase Confidence 8/10

Strong cash reserves and recent positive Phase 2 trial data for its oral weight loss drug aleniglipron signal near-term upside despite negative free cash flow.

Dec 23, 2025GPCR

Stock Weather AIBiotechnologyHealthcare

Moderna – 2025-12-23 - increase Confidence 6/10

Negative gross margin and high leverage offset by new vaccine trial breakthroughs and seasonal demand tailwinds, pointing to near-term upside.

Dec 23, 2025MRNA

Stock Weather AIBiotechnologyClinical-Stage Pharma

ABIVAX – 2025-12-22 - Increase Confidence 6/10

Strong Buy consensus and late-stage clinical catalysts outweigh negative cash flow, with near-term upside likely on ulcerative colitis Phase 3 readout anticipation.

Dec 22, 2025ABVX

Stock Weather AIBiotechnologyClinical Trials

Edgewise Therapeutics – 2025-12-22 - Increase Confidence 7/10

Strong cash position and positive Phase 1/2 data for EDG-7500 converge with upcoming investor updates, signaling near-term upside potential.

Dec 22, 2025EWTX

Stock Weather AIBiotechnologyClinical Trials

Zenas BioPharma – 2025-12-22 - Increase Confidence 8/10

Strong cash position and positive trial data converge ahead of imminent Phase 3 readout, signaling near-term upside for ZBIO.

Dec 22, 2025ZBIO

Stock Weather AIBiotechnologyClinical Stage

Edgewise Therapeutics – 2025-12-19 - Increase Confidence 7/10

Strong cash reserves and advancing clinical pipeline signal near-term upside despite ongoing losses; Q4 data readouts act as catalyst.

Dec 19, 2025EWTX

Stock Weather AIBiotechnologyMergers & Acquisitions

Amicus Therapeutics – 2025-12-19 - increase Confidence 9/10

Strong revenue growth and resolved patent litigation meet a $14.50 acquisition offer above current price, signaling near-term upside.

Dec 19, 2025FOLD

Stock Weather AIBiotechnologyClinical-Stage Pharma

Disc Medicine, Inc. – 2025-12-19 - increase Confidence 6/10

Negative free cash flow and high leverage offset by strong analyst consensus and upcoming catalysts in hematologic drug development; stock likely to rise near-term on biotech sector momentum.

Dec 19, 2025IRON

Stock Weather AIBiotechnologyClinical-Stage Pharma

Olema Pharmaceuticals – 2025-12-19 - Increase Confidence 8/10

Negative free cash flow offset by strong analyst momentum and recent trial validation, signaling near-term upside for OLMA.

Dec 19, 2025OLMA

Stock Weather AIBiotechnologyClinical Trials

Insmed – 2025-12-18 - Increase Confidence 6/10

Despite negative free cash flow and a failed Phase 2 trial, FDA approval of Brinsupri and strong analyst sentiment signal near-term upside potential.

Dec 18, 2025INSM

Stock Weather AIBiotechnologyClinical Trials

Immunome – 2025-12-15 - increase Confidence 8/10

Positive Phase 3 trial data meets primary endpoint with high statistical significance, triggering revaluation despite negative free cash flow; stock poised for near-term upside.

Dec 15, 2025IMNM

Stock Weather AIBiotechnologyClinical-Stage Pharma

Olema Pharmaceuticals – 2025-12-15 - Increase Confidence 7/10

Strong analyst consensus and robust cash reserves support upside, with palazestrant Phase 3 momentum acting as a near-term catalyst for OLMA.

Dec 15, 2025OLMA

Stock Weather AIBiotechnologyClinical-Stage Pharma

Centessa Pharmaceuticals – 2025-12-11 - Increase Confidence 7/10

Negative free cash flow offset by strong analyst backing and upcoming pipeline catalysts suggest near-term upside for CNTA.

Dec 11, 2025CNTA

Stock Weather AIBiotechnologyHealthcare

Rhythm Pharmaceuticals – 2025-12-11 - Increase Confidence 6/10

Strong gross margin and analyst buy consensus clash with negative free cash flow; no direct news catalyst, but biotech sentiment may lift RYTM in short term.

Dec 11, 2025RYTM

Stock Weather AIBiotechnologyClinical Trials

Wave Life Sciences – 2025-12-11 - Increase Confidence 8/10

Despite negative cash flow, a $250M capital raise and positive Phase 1 obesity drug data catalyze near-term upside momentum.

Dec 11, 2025WVE

Stock Weather AIBiotechnologyClinical-Stage Biopharma

Denali Therapeutics – 2025-12-10 - Increase Confidence 6/10

Negative free cash flow and high debt are offset by a $200M capital raise and bullish analyst targets, signaling near-term upside potential.

Dec 10, 2025DNLI

Stock Weather AIBiotechnologyClinical-Stage Stocks

Wave Life Sciences – 2025-12-09 - Increase Confidence 8/10

Strong analyst momentum and positive Phase 1 weight-loss data outweigh near-term cash burn, signaling upside in WVE.

Dec 9, 2025WVE

Stock Weather AIBiotechnologyClinical Trials

Structure Therapeutics – 2025-12-08 - Increase Confidence 9/10

Negative free cash flow offset by strong trial data and cash runway, triggering near-term upside momentum.

Dec 8, 2025GPCR

Stock Weather AIBiotechnologyClinical-Stage Pharma

Kymera Therapeutics – 2025-12-08 - Increase Confidence 8/10

Negative free cash flow offset by strong cash runway and recent pipeline catalysts; first patient dosed in Phase 2b trial drives near-term upside.

Dec 8, 2025KYMR